Keryx KRX-101 subpart H development plan
This article was originally published in Pharmaceutical Approvals Monthly
Keryx Biopharmaceuticals fast track diabetic nephropathy therapy KRX-101 will be submitted under subpart H, firm announces Nov. 13. The development plan allows use of surrogate endpoints in a single pivotal Phase III trial to support KRX-101's approval. Keryx is reviewing feedback from FDA and hopes to initiate the trial early next year. The firm expects the Cardio-Renal advisory committee to review the development pla
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.